Technical Support
inquiry@accegen.com
Hot Products
- In-Stock Tumor Cell Lines
- Human Orbital Fibroblasts
- Human Microglia
- Human Pulmonary Alveolar Epithelial Cells
- Human Colonic Fibroblasts
- Human Type II Alveolar Epithelial Cells
- Human Valvular Interstitial Cells
- Human Thyroid Epithelial Cells
- C57BL/6 Mouse Dermal Fibroblasts
- Human Alveolar Macrophages
- Human Dermal Fibroblasts, Adult
- Human Lung Fibroblasts, Adult
- Human Retinal Muller Cells
- Human Articular Chondrocytes
- Human Retinal Pigment Epithelial Cells
- Human Pancreatic Islets of Langerhans Cells
- Human Kidney Podocyte Cells
- Human Renal Proximal Tubule Cells
-
What do your preliminary experiments typically include?
Our preliminary experiments generally cover several core assessments to ensure project feasibility and robustness. These include confirmation of the cell genotype; close monitoring of cell growth and culture status, such as proliferation rate, morphology, and viability; evaluation of single-cell cloning capacity; rigorous sterility and mycoplasma testing; and assessment of transfection or infection efficiency to determine the most suitable gene delivery method.
-
To achieve gene loss of function, should I use knockdown (RNAi) or knockout?
The choice between gene knockdown and knockout depends on both the characteristics of the target gene and the research objective. If preliminary experiments suggest that complete knockout may cause growth arrest or cell lethality, gene knockdown is recommended to obtain a viable and informative cell model. In contrast, when the target protein remains functionally active after knockdown, or when the gene is located in a non-coding region or is highly transcribed and difficult to suppress, gene knockout represents a more definitive and reliable approach.
-
What technical approaches can you provide?
We offer a diverse range of technical platforms to meet the precise requirements of different projects. For gene knockout (KO) projects, we commonly use CRISPR RNP complexes, lentiviral delivery, or plasmid-based strategies to ensure efficient editing. For gene overexpression, high-capacity PiggyBac transposon systems or stable, high-efficiency lentiviral transduction are preferred.
We understand that each method has its unique advantages, so the final strategy is fully tailored based on your gene of interest, cell background, and specific research objectives. If you have preferences or ideas regarding the technical approach, we welcome your input to collaboratively determine the optimal construction strategy.
-
Can your luciferase-, GFP-, or RFP-reporter cell lines be stably passaged?
Yes. The reporter genes are permanently integrated into the genome and selected using antibiotics, allowing stable passaging and consistent reporter expression.
-
What types of stable cell line customization services do you offer?
We provide comprehensive and flexible stable cell line customization services tailored to your specific research needs. These include:
Gene knockout (KO)
Gene knock-in (KI)
Gene overexpression (OE)
RNA interference-mediated gene knockdown (KD)
Various reporter gene cell lines, such as fluorescent proteins (GFP/RFP) or luciferase reporters
Our scientific team collaborates closely with you to design the most suitable solution for your project.
-
What information and materials do I need to provide before constructing a stable cell line?
Before initiating a stable cell line construction project, we typically require the following key information for accurate design and evaluation: the target gene (preferably an NCBI RefSeq ID or the full CDS sequence), the host cell line, and the specific project goal (e.g., overexpression, reporter gene, or gene knock-in). For knock-in projects, providing the intended genomic integration site (such as the AAVS1 safe harbor locus) can significantly streamline and optimize the design process.
